<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000742114"><SummaryMetaData><SummaryType>Complementary and alternative medicine</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the use of high-dose vitamin C as a treatment for people with cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq">High-Dose Vitamin C (PDQ®)</SummaryURL><MainTopics><TermRef ref="CDR0000039737">ascorbic acid</TermRef></MainTopics><SecondaryTopics><TermRef ref="CDR0000372898">CAM nutritional therapy</TermRef></SecondaryTopics></SummaryMetaData><SummaryTitle>High-Dose Vitamin C (PDQ®)</SummaryTitle><AltTitle TitleType="Short">High-Dose Vitamin C</AltTitle><SummarySection id="_1"><Title>Overview</Title><Para id="_3">This <GlossaryTermRef href="CDR0000044964">complementary and alternative medicine</GlossaryTermRef> (CAM) information summary provides an overview of the use of high-<GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000439435">vitamin C</GlossaryTermRef> (also known as ascorbate or L-<GlossaryTermRef href="CDR0000439436">ascorbic acid</GlossaryTermRef>) as a treatment for people with <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef>.  This summary includes a brief history of early <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef> of high-dose vitamin C; reviews of <GlossaryTermRef href="CDR0000044512">laboratory</GlossaryTermRef>, <GlossaryTermRef href="CDR0000454774">animal</GlossaryTermRef>, and human studies; and current clinical trials.</Para><Para id="_46">This summary contains the following key information:</Para><ItemizedList id="_47" Style="bullet" Compact="No">
     <ListItem>Vitamin C is an essential <GlossaryTermRef href="CDR0000044697">nutrient</GlossaryTermRef> with redox functions at normal <GlossaryTermRef href="CDR0000045837">physiologic</GlossaryTermRef> <GlossaryTermRef href="CDR0000683342">concentrations</GlossaryTermRef>.</ListItem><ListItem>High-dose vitamin C has been studied as a treatment for cancer patients since the 1970s.</ListItem><ListItem>Laboratory studies have reported that high-dose vitamin C has redox properties and decreased <GlossaryTermRef href="CDR0000046479">cell proliferation</GlossaryTermRef> in <GlossaryTermRef href="CDR0000445079">prostate</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044521">pancreatic</GlossaryTermRef>, <GlossaryTermRef href="CDR0000046363">hepatocellular</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044237">colon</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044323">mesothelioma</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045418">neuroblastoma</GlossaryTermRef> <GlossaryTermRef href="CDR0000695994">cell lines</GlossaryTermRef>.</ListItem><ListItem>Two studies of high-dose vitamin C in cancer patients  reported improved <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef> and decreases in cancer-related <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef>.</ListItem><ListItem>Studies of vitamin C combined with other <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef> in <GlossaryTermRef href="CDR0000043996">animal models</GlossaryTermRef>  have shown mixed results.</ListItem><ListItem><GlossaryTermRef href="CDR0000046682">Intravenous</GlossaryTermRef> vitamin C has been generally well tolerated in clinical trials.</ListItem></ItemizedList><Para id="_52">Many of the medical and <GlossaryTermRef href="CDR0000044724">scientific</GlossaryTermRef> terms used in this summary are hypertext linked (at first use in each section) to the <ExternalRef xref="http://www.cancer.gov/dictionary/">NCI Dictionary of Cancer Terms</ExternalRef>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.</Para><Para id="_53">Reference citations in some <GlossaryTermRef href="CDR0000044271">PDQ</GlossaryTermRef> CAM information summaries may include links to external Web sites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the Web sites, or of any treatment or product, by the PDQ Cancer CAM Editorial Board or the <GlossaryTermRef href="CDR0000044266">National Cancer Institute</GlossaryTermRef>.</Para></SummarySection><SummarySection id="_4"><Title>General Information</Title><Para id="_6"><GlossaryTermRef href="CDR0000439435">Vitamin C</GlossaryTermRef> is an essential <GlossaryTermRef href="CDR0000044697">nutrient</GlossaryTermRef> that has redox functions, is a cofactor for several <GlossaryTermRef href="CDR0000046081">enzymes</GlossaryTermRef>, and plays an important role in the synthesis of <GlossaryTermRef href="CDR0000044196">collagen</GlossaryTermRef>.<Reference refidx="1"/>   A severe <GlossaryTermRef href="CDR0000321364">deficiency</GlossaryTermRef> in vitamin C results in scurvy, which is associated with malaise, <GlossaryTermRef href="CDR0000476353">lethargy</GlossaryTermRef>, easy bruising, and spontaneous bleeding.<Reference refidx="2"/> One of the effects of scurvy is a change in collagen structure to a thinner consistency. Normal consistency is achieved with <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef> of vitamin C.</Para><Para id="_7">In the mid-20th century, a study hypothesized that <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> may be related to changes in <GlossaryTermRef href="CDR0000044013">connective tissue</GlossaryTermRef>, which may be a consequence of vitamin C deficiency.<Reference refidx="3"/> A review of evidence published in 1974 suggested that high-<GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000439436">ascorbic acid</GlossaryTermRef> may increase host resistance and be a potential cancer <GlossaryTermRef href="CDR0000044737">therapy</GlossaryTermRef>.<Reference refidx="4"/></Para><Para id="_8">Vitamin C is synthesized from D-<GlossaryTermRef href="CDR0000044033">glucose</GlossaryTermRef> or D-galactose by many plants and animals. However, humans lack the enzyme L-gulonolactone oxidase required for ascorbic acid synthesis and must obtain vitamin C through food or <GlossaryTermRef href="CDR0000373932">supplements</GlossaryTermRef>.<Reference refidx="1"/></Para><ReferenceSection><Citation idx="1" PMID="14498993">Naidu KA: Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2: 7, 2003.</Citation><Citation idx="2">Padayatty S, Espey MG, Levine M: Vitamin C. In: Coates PM, Betz JM, Blackman MR, et al., eds.: Encyclopedia of Dietary Supplements. 2nd ed. New York, NY: Informa Healthcare, 2010, pp 821-31.</Citation><Citation idx="3" PMID="13638066">McCORMICK WJ: Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76 (4): 166-71, 1959.</Citation><Citation idx="4" PMID="4609626">Cameron E, Pauling L: The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact 9 (4): 273-83, 1974.</Citation></ReferenceSection></SummarySection><SummarySection id="_9"><Title>History</Title><Para id="_10">The earliest experience of using high-<GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000439435">vitamin C</GlossaryTermRef> (<GlossaryTermRef href="CDR0000046682">intravenous</GlossaryTermRef> [IV] and <GlossaryTermRef href="CDR0000044068">oral</GlossaryTermRef>) for <GlossaryTermRef href="CDR0000045333">cancer</GlossaryTermRef> treatment was by a Scottish <GlossaryTermRef href="CDR0000044306">surgeon</GlossaryTermRef>, Ewan Cameron, and his colleague, Allan Campbell, in the 1970s.<Reference refidx="1"/> This work led to a collaboration between Cameron and the Nobel Prize–winning chemist Linus Pauling, further promoting the potential of vitamin C <GlossaryTermRef href="CDR0000044737">therapy</GlossaryTermRef> in cancer management.<Reference refidx="2"/><Reference refidx="3"/>  As a result, two <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef> of oral vitamin C were conducted in the late 1970s and early 1980s.<Reference refidx="4"/><Reference refidx="5"/></Para><Para id="_11">(Refer to the <SummaryRef href="CDR0000742114#_16" url="/about-cancer/treatment/cam/hp/vitamin-c-pdq">Human Studies</SummaryRef> section of this summary for more information about these early studies.)</Para><Para id="_12"><GlossaryTermRef href="CDR0000044324">Pharmacokinetic</GlossaryTermRef> studies later revealed substantial differences in the maximum achieved <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> <GlossaryTermRef href="CDR0000683342">concentrations</GlossaryTermRef> of vitamin C based on the route of <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef>. When vitamin C is taken orally, <GlossaryTermRef href="CDR0000045839">plasma</GlossaryTermRef> concentrations of the vitamin are tightly controlled, with a peak achievable concentration less than 300 <GlossaryTermRef href="CDR0000372932">µM</GlossaryTermRef>. However, this tight control is bypassed with IV administration of the vitamin, resulting in very high levels of vitamin C plasma concentration (i.e., levels up to 20 <GlossaryTermRef href="CDR0000659791">mM</GlossaryTermRef>).<Reference refidx="6"/><Reference refidx="7"/>  Further research suggests that <GlossaryTermRef href="CDR0000463167">pharmacologic</GlossaryTermRef> concentrations of ascorbate, such as those achieved with IV administration, may result in <GlossaryTermRef href="CDR0000046476">cell</GlossaryTermRef> death in many <GlossaryTermRef href="CDR0000695994">cancer cell lines</GlossaryTermRef>.<Reference refidx="8"/></Para><Para id="_13">Health care <GlossaryTermRef href="CDR0000463164">practitioners</GlossaryTermRef> attending <GlossaryTermRef href="CDR0000044964">complementary and alternative medicine</GlossaryTermRef> conferences in 2006 and 2008 were surveyed about usage of high-dose IV vitamin C in patients. Of the 199 total respondents, 172 had administered vitamin C to patients. In general, IV vitamin C was commonly used to treat <GlossaryTermRef href="CDR0000045364">infections</GlossaryTermRef>,  cancer, and <GlossaryTermRef href="CDR0000321374">fatigue</GlossaryTermRef>.<Reference refidx="9"/></Para><ReferenceSection><Citation idx="1" PMID="4430016">Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974.</Citation><Citation idx="2" PMID="1068480">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976.</Citation><Citation idx="3" PMID="279931">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978.</Citation><Citation idx="4" PMID="384241">Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979.</Citation><Citation idx="5" PMID="3880867">Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985.</Citation><Citation idx="6" PMID="15068981">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.</Citation><Citation idx="7" PMID="18544557">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.</Citation><Citation idx="8" PMID="19254759">Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009.</Citation><Citation idx="9" PMID="20628650">Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_14"><Title>Laboratory/Animal/Preclinical Studies</Title><SummarySection id="_20"><Title><Emphasis>In Vitro</Emphasis> Studies</Title><Para id="_21">Numerous studies have demonstrated that <GlossaryTermRef href="CDR0000463167">pharmacological</GlossaryTermRef> <GlossaryTermRef href="CDR0000044664">doses</GlossaryTermRef> of <GlossaryTermRef href="CDR0000439436">ascorbic acid</GlossaryTermRef> (0.1–100 <GlossaryTermRef href="CDR0000659791">mM)</GlossaryTermRef>   decrease <GlossaryTermRef href="CDR0000046479">cell proliferation</GlossaryTermRef> in a variety of <GlossaryTermRef href="CDR0000695994">cancer cell lines</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Specifically, decreases in <GlossaryTermRef href="CDR0000046476">cell</GlossaryTermRef> proliferation after ascorbic acid treatment have been reported for <GlossaryTermRef href="CDR0000445079">prostate</GlossaryTermRef>,<Reference refidx="6"/> <GlossaryTermRef href="CDR0000044074">pancreatic</GlossaryTermRef>,<Reference refidx="7"/><Reference refidx="8"/> <GlossaryTermRef href="CDR0000046363">hepatocellular</GlossaryTermRef>,<Reference refidx="9"/> <GlossaryTermRef href="CDR0000044237">colon</GlossaryTermRef>,<Reference refidx="10"/> <GlossaryTermRef href="CDR0000044323">mesothelioma</GlossaryTermRef>,<Reference refidx="11"/> and <GlossaryTermRef href="CDR0000045418">neuroblastoma</GlossaryTermRef> <Reference refidx="12"/> cell lines.</Para><Para id="_23">The potential mechanisms through which treatment with high-dose ascorbic acid may exert its effects on cancer cells have been extensively investigated. Several studies have demonstrated that the <Emphasis><GlossaryTermRef href="CDR0000045733">in vitro</GlossaryTermRef></Emphasis> direct <GlossaryTermRef href="CDR0000044020">cytotoxic</GlossaryTermRef> effect of ascorbic acid on various types of cancer cells is mediated through a <GlossaryTermRef href="CDR0000643008">chemical</GlossaryTermRef> reaction that generates <GlossaryTermRef href="CDR0000044113">hydrogen peroxide</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="7"/> Reviewed in <Reference refidx="13"/><Reference refidx="14"/> Treating <GlossaryTermRef href="CDR0000044237">colon cancer</GlossaryTermRef> cells with 2 mM to 3 mM of ascorbic acid resulted in downregulation of specificity protein (Sp) <GlossaryTermRef href="CDR0000390290">transcription</GlossaryTermRef> factors and Sp-regulated <GlossaryTermRef href="CDR0000045693">genes</GlossaryTermRef> involved in cancer <GlossaryTermRef href="CDR0000044078">progression</GlossaryTermRef>.<Reference refidx="10"/> One study suggested that ascorbate-mediated prostate cancer cell death may occur through activation of an <GlossaryTermRef href="CDR0000561319">autophagy</GlossaryTermRef> pathway.<Reference refidx="6"/> </Para><Para id="_24">Differences in <GlossaryTermRef href="CDR0000372925">chemosensitivity</GlossaryTermRef> to ascorbate treatment in <GlossaryTermRef href="CDR0000444971">breast cancer</GlossaryTermRef> cell lines may depend on expression of the <GlossaryTermRef href="CDR0000044731">sodium</GlossaryTermRef>-dependent <GlossaryTermRef href="CDR0000439435">vitamin C</GlossaryTermRef> transporter 2 (SVCT-2).<Reference refidx="15"/></Para><Para id="_54">Research has suggested that pharmacological doses of ascorbic acid enhance the effects of <GlossaryTermRef href="CDR0000046018">arsenic trioxide</GlossaryTermRef> on <GlossaryTermRef href="CDR0000445074">ovarian cancer</GlossaryTermRef> cells,<Reference refidx="16"/> gemcitabine on pancreatic cancer cells,<Reference refidx="8"/> and combination treatment of <GlossaryTermRef href="CDR0000045347">gemcitabine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000687212">epigallocatechin-3-gallate</GlossaryTermRef> (EGCG) on mesothelioma cells.<Reference refidx="17"/></Para><Para id="_25">Findings from one study reported in 2012 suggested that high-dose ascorbate increases radiosensitivity of <GlossaryTermRef href="CDR0000045699">glioblastoma multiforme</GlossaryTermRef> cells, resulting in more cell death than from <GlossaryTermRef href="CDR0000044971">radiation therapy</GlossaryTermRef> alone.<Reference refidx="18"/></Para><Para id="_26">However, not all studies combining vitamin C with <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef> have shown improved outcomes.  Treating <GlossaryTermRef href="CDR0000045343">leukemia</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045368">lymphoma</GlossaryTermRef> cells with dehydroascorbic acid (the <GlossaryTermRef href="CDR0000654996">oxidized</GlossaryTermRef> form of vitamin C that increases levels of <GlossaryTermRef href="CDR0000044047">intracellular</GlossaryTermRef> ascorbic acid) reduced the cytotoxic effects  of various <GlossaryTermRef href="CDR0000044816">antineoplastic</GlossaryTermRef> agents tested, including <GlossaryTermRef href="CDR0000045140">doxorubicin</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045393">methotrexate</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000045230">cisplatin</GlossaryTermRef> (relative reductions in cytotoxicity ranged from 30% to 70%).<Reference refidx="19"/> In another study, <GlossaryTermRef href="CDR0000045793">multiple myeloma</GlossaryTermRef> cells were treated with <GlossaryTermRef href="CDR0000269133">bortezomib</GlossaryTermRef> and/or <GlossaryTermRef href="CDR0000045839">plasma</GlossaryTermRef> obtained from healthy volunteers who had taken vitamin C <GlossaryTermRef href="CDR0000373932">supplements</GlossaryTermRef>. Cells treated with a combination of bortezomib and volunteers’ plasma exhibited lower cytotoxicity than did cells treated with bortezomib alone.<Reference refidx="20"/></Para></SummarySection><SummarySection id="_27"><Title>Animal Studies</Title><Para id="_28">Studies have demonstrated <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> growth inhibition after treatment with pharmacological ascorbate in <GlossaryTermRef href="CDR0000043996">animal models</GlossaryTermRef> of pancreatic cancer,<Reference refidx="1"/><Reference refidx="7"/><Reference refidx="8"/> <GlossaryTermRef href="CDR0000044242">liver cancer</GlossaryTermRef>,<Reference refidx="3"/> prostate cancer,<Reference refidx="21"/> <GlossaryTermRef href="CDR0000045562">sarcoma</GlossaryTermRef>,<Reference refidx="22"/> mesothelioma,<Reference refidx="11"/> and ovarian cancer.<Reference refidx="4"/></Para><Para id="_29">The effects of high-dose ascorbic acid in combination with <GlossaryTermRef href="CDR0000044930">standard treatments</GlossaryTermRef> on tumors have been investigated. In a <GlossaryTermRef href="CDR0000561606">mouse model</GlossaryTermRef> of pancreatic cancer, the combination of gemcitabine (30 or 60 <GlossaryTermRef href="CDR0000044213">mg</GlossaryTermRef>/<GlossaryTermRef href="CDR0000044576">kg</GlossaryTermRef> every 4 days) and ascorbate (4 <GlossaryTermRef href="CDR0000373014">g</GlossaryTermRef>/kg daily) resulted in greater decreases in <GlossaryTermRef href="CDR0000467873">tumor volume</GlossaryTermRef> and weight, compared with gemcitabine treatment alone.<Reference refidx="8"/> According to a study reported in 2012, ascorbate enhanced the cancer cell–killing effects of <GlossaryTermRef href="CDR0000045238">photodynamic therapy</GlossaryTermRef> in mice <GlossaryTermRef href="CDR0000044678">injected</GlossaryTermRef> with breast cancer cells.<Reference refidx="23"/> A study of mouse models of ovarian cancer found that ascorbate enhanced the tumor inhibitory effect of <GlossaryTermRef href="CDR0000045182">carboplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045258">paclitaxel</GlossaryTermRef>, <GlossaryTermRef href="CDR0000346494">first-line</GlossaryTermRef> chemotherapy used in ovarian cancer.<Reference refidx="24"/></Para><Para id="_48">Using <GlossaryTermRef href="CDR0000045797">N-acetylcysteine</GlossaryTermRef> (NAC) and vitamin C, researchers showed in 2007 that these <GlossaryTermRef href="CDR0000422394">compounds</GlossaryTermRef>, both thought to act predominantly as <GlossaryTermRef href="CDR0000043997">antioxidants</GlossaryTermRef>, may have antitumorigenic actions <Emphasis><GlossaryTermRef href="CDR0000046352">in vivo</GlossaryTermRef></Emphasis> by decreasing levels of <GlossaryTermRef href="CDR0000302460">hypoxia</GlossaryTermRef>-inducible factor (HIF)-1, a transcription factor that targets <GlossaryTermRef href="CDR0000044222">vascular endothelial growth factor</GlossaryTermRef> (VEGF) and plays a role in <GlossaryTermRef href="CDR0000046529">angiogenesis</GlossaryTermRef>.<Reference refidx="25"/></Para><Para id="_30">There have also been reports of animal studies in which vitamin C has interfered with the anticancer activity of various drugs.  In a study reported in 2008, <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef> of dehydroascorbic acid to lymphoma-<GlossaryTermRef href="CDR0000044095">xenograft</GlossaryTermRef> mice prior to doxorubicin treatment resulted in significantly larger tumors than did treatment with doxorubicin alone.<Reference refidx="19"/> Notably, this study used dehydroascorbate, the oxidized form of vitamin C that is known to be transported actively into cells and then reduced to vitamin C. Treating multiple myeloma xenograft mice with a combination of <GlossaryTermRef href="CDR0000044068">oral</GlossaryTermRef> vitamin C and bortezomib resulted in significantly greater tumor volume than did treatment with bortezomib alone.<Reference refidx="20"/> This increase in tumor volume was caused by a chemical reaction that occurs in the <GlossaryTermRef href="CDR0000046189">gastrointestinal tract</GlossaryTermRef> but does not appear to be relevant to <GlossaryTermRef href="CDR0000046682">intravenous</GlossaryTermRef> administration.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="21672627">Chen P, Stone J, Sullivan G, et al.: Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med 51 (3): 681-7, 2011.</Citation><Citation idx="2" PMID="16157892">Chen Q, Espey MG, Krishna MC, et al.: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102 (38): 13604-9, 2005.</Citation><Citation idx="3" PMID="19254759">Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009.</Citation><Citation idx="4" PMID="18678913">Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008.</Citation><Citation idx="5" PMID="20694726">Frömberg A, Gutsch D, Schulze D, et al.: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67 (5): 1157-66, 2011.</Citation><Citation idx="6" PMID="22205155">Chen P, Yu J, Chalmers B, et al.: Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 23 (4): 437-44, 2012.</Citation><Citation idx="7" PMID="20068072">Du J, Martin SM, Levine M, et al.: Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16 (2): 509-20, 2010.</Citation><Citation idx="8" PMID="21402145">Espey MG, Chen P, Chalmers B, et al.: Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50 (11): 1610-9, 2011.</Citation><Citation idx="9" PMID="19932582">Lin ZY, Chuang WL: Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 64 (5): 348-51, 2010.</Citation><Citation idx="10" PMID="21919647">Pathi SS, Lei P, Sreevalsan S, et al.: Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer 63 (7): 1133-42, 2011.</Citation><Citation idx="11" PMID="20171954">Takemura Y, Satoh M, Satoh K, et al.: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394 (2): 249-53, 2010.</Citation><Citation idx="12" PMID="22469841">Hardaway CM, Badisa RB, Soliman KF: Effect of ascorbic acid and hydrogen peroxide on mouse neuroblastoma cells. Mol Med Report 5 (6): 1449-52, 2012.</Citation><Citation idx="13" PMID="22728050">Du J, Cullen JJ, Buettner GR: Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 1826 (2): 443-57, 2012.</Citation><Citation idx="14" PMID="22332036">Levine M, Padayatty SJ, Espey MG: Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2 (2): 78-88, 2011.</Citation><Citation idx="15" PMID="22665050">Hong SW, Lee SH, Moon JH, et al.: SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 32 (12): 1508-17, 2013.</Citation><Citation idx="16" PMID="21455570">Ong PS, Chan SY, Ho PC: Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation. Int J Oncol 38 (6): 1731-9, 2011.</Citation><Citation idx="17" PMID="21645609">Martinotti S, Ranzato E, Burlando B: In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25 (8): 1568-74, 2011.</Citation><Citation idx="18" PMID="22342518">Herst PM, Broadley KW, Harper JL, et al.: Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med 52 (8): 1486-93, 2012.</Citation><Citation idx="19" PMID="18829561">Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008.</Citation><Citation idx="20" PMID="19369963">Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009.</Citation><Citation idx="21" PMID="20554995">Pollard HB, Levine MA, Eidelman O, et al.: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24 (3): 249-55, 2010 May-Jun.</Citation><Citation idx="22" PMID="19671184">Yeom CH, Lee G, Park JH, et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7: 70, 2009.</Citation><Citation idx="23" PMID="22246986">Wei Y, Song J, Chen Q, et al.: Enhancement of photodynamic antitumor effect with pro-oxidant ascorbate. Lasers Surg Med 44 (1): 69-75, 2012.</Citation><Citation idx="24" PMID="24500406">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.</Citation><Citation idx="25" PMID="17785204">Gao P, Zhang H, Dinavahi R, et al.: HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (3): 230-8, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_16"><Title>Human/Clinical Studies</Title><SummarySection id="_31"><Title>Early Ascorbate-Only Trials</Title><Para id="_32">In the early 1970s, a <GlossaryTermRef href="CDR0000285747">consecutive case series</GlossaryTermRef> was conducted in which 50 <GlossaryTermRef href="CDR0000478743">advanced-cancer</GlossaryTermRef> patients were treated with large <GlossaryTermRef href="CDR0000044664">doses</GlossaryTermRef> of <GlossaryTermRef href="CDR0000439436">ascorbic acid</GlossaryTermRef>.<Reference refidx="1"/> These patients began ascorbic acid treatment after <GlossaryTermRef href="CDR0000044198">conventional therapies</GlossaryTermRef> were deemed unlikely to be effective. Patients received <GlossaryTermRef href="CDR0000046682">intravenous</GlossaryTermRef> (IV) ascorbic acid (10 <GlossaryTermRef href="CDR0000373014">g</GlossaryTermRef>/day for 10 consecutive days; some patients received higher doses), <GlossaryTermRef href="CDR0000044068">oral</GlossaryTermRef> ascorbic acid (10 g/day), or both. The subjects exhibited a wide variety of <GlossaryTermRef href="CDR0000044085">responses</GlossaryTermRef> to treatment, including no or minimal response, <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> <GlossaryTermRef href="CDR0000046039">regression</GlossaryTermRef>, and tumor <GlossaryTermRef href="CDR0000373015">hemorrhage</GlossaryTermRef>. However, the authors noted that lack of controls prevented definitive assignment of any beneficial responses to the ascorbic acid treatment. A <GlossaryTermRef href="CDR0000044007">case report</GlossaryTermRef> published in 1975 detailed one of the patients who had experienced tumor regression.<Reference refidx="2"/> Diagnosed with reticulum <GlossaryTermRef href="CDR0000046476">cell</GlossaryTermRef> <GlossaryTermRef href="CDR0000045562">sarcoma</GlossaryTermRef>, the patient exhibited improvement in well-being and resolution of <GlossaryTermRef href="CDR0000270740">lung</GlossaryTermRef> masses after being treated with ascorbic acid. When the patient's daily dose of ascorbic acid was reduced, some of signs of the disease returned; however, <GlossaryTermRef href="CDR0000045867">remission</GlossaryTermRef> was achieved again after the patient reverted to the higher initial dose.</Para><Para id="_33">A larger <GlossaryTermRef href="CDR0000044006">case series</GlossaryTermRef> of terminal cancer patients treated with ascorbate was reported in 1976. In this study, 100 terminal cancer patients (50 of whom were reported on previously)  <Reference refidx="1"/> were treated with ascorbate (10 g/day for 10 days IV, then orally) and compared with 1,000 matched controls from the same hospital. The <GlossaryTermRef href="CDR0000285974">mean survival</GlossaryTermRef> time for ascorbate-treated patients was 300 days longer than that of the matched controls.<Reference refidx="3"/><Reference refidx="4"/></Para><Para id="_34">Two studies tried to reproduce earlier results. These studies were <GlossaryTermRef href="CDR0000045858">randomized</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044840">placebo-controlled</GlossaryTermRef> trials in which cancer patients received either 10 g oral <GlossaryTermRef href="CDR0000439435">vitamin C</GlossaryTermRef> or placebo daily until signs of cancer progression. At the end of each study, no <GlossaryTermRef href="CDR0000390271">significant</GlossaryTermRef> differences were noted between the two ascorbate-treated and placebo-treated groups for <GlossaryTermRef href="CDR0000045022">symptoms</GlossaryTermRef>, <GlossaryTermRef href="CDR0000044174">performance status</GlossaryTermRef>, or <GlossaryTermRef href="CDR0000044301">survival</GlossaryTermRef>.<Reference refidx="5"/><Reference refidx="6"/></Para></SummarySection><SummarySection id="_35"><Title>Recent Ascorbate-Only Trials</Title><Para id="_57">One study reported three case reports of cancer patients who received IV vitamin C as their main <GlossaryTermRef href="CDR0000044737">therapy</GlossaryTermRef>. During vitamin C therapy, the patients used additional treatments, including <GlossaryTermRef href="CDR0000044744">vitamins</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045787">minerals</GlossaryTermRef>, and <GlossaryTermRef href="CDR0000367458">botanicals</GlossaryTermRef>.  According to the authors, the cases were reviewed in accordance with the <ExternalRef xref="http://cam.cancer.gov/best_case_intro.html"> NCI Best Case Series guidelines</ExternalRef>. <GlossaryTermRef href="CDR0000467841">Histopathologic</GlossaryTermRef> examination suggested poor <GlossaryTermRef href="CDR0000045849">prognoses</GlossaryTermRef> for these patients, but they had long survival times after being treated with IV vitamin C.<Reference refidx="7"/> Vitamin C was given at doses ranging from 15 g to 65 g, initially once or twice a week for several months; two patients then received it less frequently for 1 to 4 years.</Para><Para id="_36">Two studies demonstrated that IV vitamin C treatment resulted in improved <GlossaryTermRef href="CDR0000045417">quality of life</GlossaryTermRef> and decreases in cancer-related <GlossaryTermRef href="CDR0000046580">side effects</GlossaryTermRef> in cancer patients.<Reference refidx="8"/><Reference refidx="9"/></Para><Para id="_38">Studies have shown that vitamin C can be safely administered to healthy volunteers or cancer patients at doses up to 1.5 g/<GlossaryTermRef href="CDR0000044576">kg</GlossaryTermRef> and with <GlossaryTermRef href="CDR0000046171">screening</GlossaryTermRef> to eliminate treating individuals with <GlossaryTermRef href="CDR0000045873">risk factors</GlossaryTermRef> for <GlossaryTermRef href="CDR0000445093">toxicity</GlossaryTermRef> (e.g., <GlossaryTermRef href="CDR0000748114">glucose-6-phosphate dehydrogenase deficiency</GlossaryTermRef>, renal diseases, or urolithiasis). These studies have also found that <GlossaryTermRef href="CDR0000045839">plasma</GlossaryTermRef> concentrations of vitamin C are higher with IV <GlossaryTermRef href="CDR0000478733">administration</GlossaryTermRef> than with oral administration and are maintained for more than 4 hours.<Reference refidx="10"/><Reference refidx="11"/></Para></SummarySection><SummarySection id="_39"><Title>Ascorbate-Combination Trials</Title><Para id="_40">A <GlossaryTermRef href="CDR0000045830">phase I</GlossaryTermRef> study published in 2012 examined the safety and <GlossaryTermRef href="CDR0000346517">efficacy</GlossaryTermRef> of combining IV ascorbate with <GlossaryTermRef href="CDR0000045347">gemcitabine</GlossaryTermRef> and <GlossaryTermRef href="CDR0000508929">erlotinib</GlossaryTermRef> in <GlossaryTermRef href="CDR0000045511">stage IV pancreatic cancer</GlossaryTermRef> patients. Fourteen subjects entered the study and planned to receive IV gemcitabine (1,000 <GlossaryTermRef href="CDR0000044213">mg</GlossaryTermRef>/m<Superscript>2</Superscript> over 30 minutes, once a week for 7 weeks), oral erlotinib (100 mg daily for 8 weeks), and IV ascorbate (50 g/<GlossaryTermRef href="CDR0000045738">infusion</GlossaryTermRef>, 75 g/infusion, or 100 g/infusion 3 times per week for 8 weeks). Minimal <GlossaryTermRef href="CDR0000044922">adverse effects</GlossaryTermRef> were reported for ascorbic acid treatment. Five subjects received fewer than 18 of the planned 24 ascorbate infusions and thus did not have <GlossaryTermRef href="CDR0000044671">follow-up</GlossaryTermRef> <GlossaryTermRef href="CDR0000046361">imaging</GlossaryTermRef> to assess response. Three of those patients had clinically determined <GlossaryTermRef href="CDR0000045850">progressive disease</GlossaryTermRef>. All of the other nine patients had repeat imaging to assess tumor size, and each met the criteria for having <GlossaryTermRef href="CDR0000045884">stable disease</GlossaryTermRef>.<Reference refidx="12"/></Para><Para id="_62">A 2013 phase I <GlossaryTermRef href="CDR0000044195">clinical study</GlossaryTermRef> evaluated the safety of combining pharmacological ascorbate with gemcitabine in treating stage IV pancreatic cancer patients. During each 4-week cycle, patients received gemcitabine weekly for 3 weeks (1,000 mg/m<Superscript>2</Superscript> over 30 minutes) and twice weekly ascorbate infusions for 4 weeks (15 g over 30 minutes during the first week, followed by weekly escalations in dose until plasma levels reached at least 350 mg/dL [20 <GlossaryTermRef href="CDR0000659791">mM</GlossaryTermRef>]). Among nine patients, mean <GlossaryTermRef href="CDR0000044782">progression-free survival</GlossaryTermRef> was 26 weeks and <GlossaryTermRef href="CDR0000655245">overall survival</GlossaryTermRef> was 12 months. The combination treatment was well tolerated, and no significant adverse events were reported.<Reference refidx="13"/></Para><Para id="_68">In 2014, a <GlossaryTermRef href="CDR0000045832">phase I/IIA</GlossaryTermRef> clinical trial evaluated the toxicities of combining IV ascorbate with <GlossaryTermRef href="CDR0000045182">carboplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045258">paclitaxel</GlossaryTermRef> in <GlossaryTermRef href="CDR0000045901">stage III</GlossaryTermRef>/<GlossaryTermRef href="CDR0000045902">IV ovarian cancer</GlossaryTermRef>. Twenty-seven patients were randomly assigned to receive either <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef> alone or chemotherapy and IV vitamin C concurrently. Chemotherapy was given for 6 months, and IV vitamin C was given for 12 months. The addition of IV vitamin C was associated with  reduced chemotherapy-related toxicities.<Reference refidx="14"/></Para><Para id="_41">Trials of high-dose IV vitamin C with other <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef> are ongoing.<Reference refidx="12"/><Reference refidx="14"/> A number of studies have included IV ascorbic acid treatment (1,000 mg) with <GlossaryTermRef href="CDR0000046018">arsenic trioxide</GlossaryTermRef> <GlossaryTermRef href="CDR0000045864">regimens</GlossaryTermRef>, with mixed results. The combination therapies were well tolerated and suggested beneficial effects in <GlossaryTermRef href="CDR0000045793">multiple myeloma</GlossaryTermRef> patients, although the specific contribution of vitamin C could not be determined.<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/>  However, similar combination regimens resulted in severe side effects and <GlossaryTermRef href="CDR0000045669">disease progression</GlossaryTermRef> in patients with <GlossaryTermRef href="CDR0000046347">acute myeloid leukemia</GlossaryTermRef>,<Reference refidx="19"/> <GlossaryTermRef href="CDR0000350245">refractory</GlossaryTermRef> <GlossaryTermRef href="CDR0000044058">metastatic</GlossaryTermRef> <GlossaryTermRef href="CDR0000444983">colorectal cancer</GlossaryTermRef>,<Reference refidx="20"/> and metastatic <GlossaryTermRef href="CDR0000045135">melanoma</GlossaryTermRef>.<Reference refidx="21"/></Para></SummarySection><SummarySection id="_TrialSearch_16_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_16_19">Check NCI’s list of cancer clinical trials for cancer CAM clinical trials on <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?idtype=1&amp;id=39737&amp;tt=0&amp;format=2">ascorbic acid</ExternalRef> that are actively enrolling patients.</Para><Para id="_TrialSearch_16_15">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="4430016">Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974.</Citation><Citation idx="2" PMID="1104207">Cameron E, Campbell A, Jack T: The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 11 (5): 387-93, 1975.</Citation><Citation idx="3" PMID="1068480">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976.</Citation><Citation idx="4" PMID="279931">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978.</Citation><Citation idx="5" PMID="384241">Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979.</Citation><Citation idx="6" PMID="3880867">Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985.</Citation><Citation idx="7" PMID="16567755">Padayatty SJ, Riordan HD, Hewitt SM, et al.: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (7): 937-42, 2006.</Citation><Citation idx="8" PMID="22021693">Vollbracht C, Schneider B, Leendert V, et al.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 25 (6): 983-90, 2011 Nov-Dec.</Citation><Citation idx="9" PMID="17297243">Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22 (1): 7-11, 2007.</Citation><Citation idx="10" PMID="15068981">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.</Citation><Citation idx="11" PMID="18544557">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.</Citation><Citation idx="12" PMID="22272248">Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012.</Citation><Citation idx="13" PMID="23381814">Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013.</Citation><Citation idx="14" PMID="24500406">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.</Citation><Citation idx="15" PMID="16720927">Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006.</Citation><Citation idx="16" PMID="17363530">Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007.</Citation><Citation idx="17" PMID="19041063">Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008.</Citation><Citation idx="18" PMID="17010047">Berenson JR, Boccia R, Siegel D, et al.: Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135 (2): 174-83, 2006.</Citation><Citation idx="19" PMID="21815182">Welch JS, Klco JM, Gao F, et al.: Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol 86 (9): 796-800, 2011.</Citation><Citation idx="20" PMID="17497326">Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 46 (4): 557-61, 2007.</Citation><Citation idx="21" PMID="18337652">Bael TE, Peterson BL, Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 18 (2): 147-51, 2008.</Citation></ReferenceSection></SummarySection><SummarySection id="_18"><Title>Adverse Effects</Title><Para id="_19"><GlossaryTermRef href="CDR0000046682">Intravenous</GlossaryTermRef> (IV) high-<GlossaryTermRef href="CDR0000044664">dose</GlossaryTermRef> <GlossaryTermRef href="CDR0000439436">ascorbic acid</GlossaryTermRef> has been generally well tolerated in <GlossaryTermRef href="CDR0000045961">clinical trials</GlossaryTermRef>.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/> <GlossaryTermRef href="CDR0000462925">Renal failure</GlossaryTermRef> following ascorbic acid treatment has been reported in patients with preexisting renal <GlossaryTermRef href="CDR0000407758">disorders</GlossaryTermRef>.<Reference refidx="9"/></Para><Para id="_42"><GlossaryTermRef href="CDR0000044007">Case reports</GlossaryTermRef> have indicated that patients with <GlossaryTermRef href="CDR0000748114">glucose-6-phosphate dehydrogenase (G-6-PD) deficiency</GlossaryTermRef> should not receive high doses of <GlossaryTermRef href="CDR0000439435">vitamin C</GlossaryTermRef> because of the risk of developing <GlossaryTermRef href="CDR0000687883">hemolysis</GlossaryTermRef>.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/></Para><Para id="_43">Vitamin C may increase <GlossaryTermRef href="CDR0000044225">bioavailability</GlossaryTermRef> of <GlossaryTermRef href="CDR0000446805">iron</GlossaryTermRef>, and high doses of the vitamin are not recommended for patients with <GlossaryTermRef href="CDR0000446804">hemochromatosis</GlossaryTermRef>.<Reference refidx="13"/></Para><SummarySection id="_49"><Title>Drug Interactions</Title><Para id="_50">When administered in high doses, vitamin C may result in adverse interactions with some anticancer agents. These interactions have primarily been detected in <GlossaryTermRef href="CDR0000044517">preclinical studies</GlossaryTermRef>. A 2013 phase I clinical study evaluated the safety of combining high-dose IV ascorbate with <GlossaryTermRef href="CDR0000045347">gemcitabine</GlossaryTermRef> in stage IV pancreatic cancer patients. The combination therapy was well tolerated by patients, and no significant adverse events were reported.<Reference refidx="14"/></Para><Para id="_51"><Emphasis><GlossaryTermRef href="CDR0000045733">In vitro</GlossaryTermRef></Emphasis> and <Emphasis><GlossaryTermRef href="CDR0000046352">in vivo</GlossaryTermRef></Emphasis> <GlossaryTermRef href="CDR0000454774">animal studies</GlossaryTermRef> have suggested that combining <GlossaryTermRef href="CDR0000044068">oral</GlossaryTermRef> vitamin C with <GlossaryTermRef href="CDR0000269133">bortezomib</GlossaryTermRef> interferes with the drug’s ability to act as a <GlossaryTermRef href="CDR0000393541">proteasome inhibitor</GlossaryTermRef> and blocks bortezomib-initiated <GlossaryTermRef href="CDR0000046524">apoptosis</GlossaryTermRef>.<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/> This interference occurred even with the oral administration of vitamin C (40 <GlossaryTermRef href="CDR0000044213">mg</GlossaryTermRef>/<GlossaryTermRef href="CDR0000044576">kg</GlossaryTermRef>/day)  to animals. Studies in <GlossaryTermRef href="CDR0000556412">cell culture</GlossaryTermRef> and performed by adding <GlossaryTermRef href="CDR0000270735">blood</GlossaryTermRef> <GlossaryTermRef href="CDR0000045839">plasma</GlossaryTermRef> from healthy volunteers given  oral vitamin C (1 <GlossaryTermRef href="CDR0000373014">g</GlossaryTermRef>/day) also showed a <GlossaryTermRef href="CDR0000390271">significant</GlossaryTermRef> decrease in bortezomib’s growth inhibitory effect on <GlossaryTermRef href="CDR0000045793">multiple myeloma</GlossaryTermRef> cells. Another study found similar results. Plasma from healthy volunteers who took 1 g of oral vitamin C per day was shown to decrease bortezomib growth inhibition in multiple myeloma cells and to block its inhibitory effect on 20S proteasome activity.<Reference refidx="17"/> However, a study that utilized mice harboring human <GlossaryTermRef href="CDR0000445079">prostate cancer</GlossaryTermRef> cell <GlossaryTermRef href="CDR0000044095">xenografts</GlossaryTermRef> failed to find any significant effect of oral vitamin C (40 mg/kg/day or 500 mg/kg/day) on the <GlossaryTermRef href="CDR0000046634">tumor</GlossaryTermRef> growth inhibitory action of bortezomib.<Reference refidx="18"/>  </Para><Para id="_55">Several studies have been performed to assess the potential <GlossaryTermRef href="CDR0000330184">synergistic</GlossaryTermRef> or inhibitory action of vitamin C on certain <GlossaryTermRef href="CDR0000045214">chemotherapy</GlossaryTermRef> <GlossaryTermRef href="CDR0000348921">drugs</GlossaryTermRef>, with variable results. A series of studies in cell culture and in animals bearing tumors has shown that when given at high concentrations or dosages, dehydroascorbic acid (an oxidized form of vitamin C) can interfere with the <GlossaryTermRef href="CDR0000044020">cytotoxic</GlossaryTermRef> effects of several chemotherapy drugs.<Reference refidx="19"/>  However, dehydroascorbic acid is generally present only at low concentrations in <GlossaryTermRef href="CDR0000373932">dietary supplements</GlossaryTermRef> and fresh foods.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15068981">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.</Citation><Citation idx="2" PMID="18544557">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.</Citation><Citation idx="3" PMID="18678913">Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008.</Citation><Citation idx="4" PMID="22272248">Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012.</Citation><Citation idx="5" PMID="16720927">Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006.</Citation><Citation idx="6" PMID="17363530">Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007.</Citation><Citation idx="7" PMID="19041063">Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008.</Citation><Citation idx="8" PMID="24500406">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.</Citation><Citation idx="9" PMID="20628650">Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010.</Citation><Citation idx="10" PMID="1138591">Campbell GD Jr, Steinberg MH, Bower JD: Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 82 (6): 810, 1975.</Citation><Citation idx="11" PMID="1976956">Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 336 (8720): 944, 1990.</Citation><Citation idx="12" PMID="8490379">Rees DC, Kelsey H, Richards JD: Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306 (6881): 841-2, 1993.</Citation><Citation idx="13" PMID="9867745">Barton JC, McDonnell SM, Adams PC, et al.: Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 129 (11): 932-9, 1998.</Citation><Citation idx="14" PMID="23381814">Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013.</Citation><Citation idx="15" PMID="16397052">Zou W, Yue P, Lin N, et al.: Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12 (1): 273-80, 2006.</Citation><Citation idx="16" PMID="18176107">Llobet D, Eritja N, Encinas M, et al.: Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19 (2): 115-24, 2008.</Citation><Citation idx="17" PMID="19369963">Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009.</Citation><Citation idx="18" PMID="21400028">Bannerman B, Xu L, Jones M, et al.: Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 68 (5): 1145-54, 2011.</Citation><Citation idx="19" PMID="18829561">Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008.</Citation></ReferenceSection></SummarySection><SummarySection id="_44"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (05/13/2015)</Title><Para id="_56">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</Para><Para id="_77">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/cancer-cam-board">PDQ Cancer Complementary and Alternative Medicine Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000742114#_AboutThis_1" url="http://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of high-dose vitamin C in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/cancer-cam-board">PDQ Cancer Complementary and Alternative Medicine Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewer for High-Dose Vitamin C is:</Para><ItemizedList Style="bullet"><ListItem>Jeffrey D. White, MD (National Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Cancer Complementary and Alternative Medicine Editorial Board uses a <SummaryRef href="CDR0000256874" url="/publications/pdq/levels-evidence/cam">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® High-Dose Vitamin C. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq">http://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection><DateFirstPublished>2013-02-08</DateFirstPublished><DateLastModified>2015-05-13</DateLastModified></Summary>
